We are international
Donate
• about myeloma TEXT SIZE   
publications    back

Myeloma Minute
August 14, 2014
08.14.14


August 14, 2014
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF
 



This week's question: How can Revlimid's diarrhea side effect be handled?


Upcoming Events



August 22 - 23, 2014
Patient & Family Seminar
Los Angeles, California

Saturday, August 23, 2014
A Day at the Races
Oceanport, New Jersey



Thursday, August 28, 2014
Living Well with Myeloma: Understanding the Immune System and Lab Values in Myeloma

Saturday, November 8, 2014 Save the Date!
8th Annual Comedy Celebration
Los Angeles, California

 

 

 

x

MRD Testing: Have We Found the Method We Need?

Two types of tests are currently in development to measure minimal residual disease (MRD) in myeloma patients: a sophisticated new flow cytometry test and a molecular test. In his blog this week, IMF Chairman Dr. Brian Durie examines the differences between the two and explains why, in his opinion, the flow cytometry test is superior. READ MORE
x

FDA Approves Use of Velcade for Retreatment of Myeloma

The US FDA has approved the use of Velcade for retreatment of myeloma patients who have previously responded to Velcade and have relapsed at least six months after their prior treatment. The expanded approval was granted based on data from a phase II clinical trial. This approval includes IV and subcutaneous forms of Velcade. READ MORE

x

More on Measles Virotherapy for Myeloma

Last week, the popular radio show Science Friday broadcast on National Public Radio explored the exciting science around cancer virotherapy. Guest Dr. Stephen Russell of the Mayo Clinic shared his experience treating myeloma patients with massive doses of the measles virus, which Dr. Durie has blogged about in the past. To listen to the radio show, CLICK HERE.
x

Help Us Reach 100 Co-Sponsors This Month

August is the perfect time to schedule an in-district meeting with your US representative to ask for his or her support of HR 1801, the Cancer Drug Coverage Parity Act. With Congress in recess this month, your US representatives are spending time in your district. The IMF Advocacy Team is here to help make it easy for you, with resources available to inform you on the issue and prepare you prior to your meeting. Please contact Ray Wezik for guidance and CLICK HERE to learn more about oral anticancer treatment access legislation.

 

Join Our Mailing List

 

 

 

 

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe
www.myeloma.org

 related articles